Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Decreased AChR-Ab titers correlated with improved myasthenia gravis symptoms, especially in ADL scores, within the first 3 months of treatment. The study found no baseline correlation between AChR ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor ...

Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent publication in mAbs. The study showcases the drug’s high-affinity binding ...

ADCs vary in components and mechanisms, influencing outcomes and toxicity; targeting HER2 and exploring combinations are promising strategies. Recent phase 1 study of SHR-A2102 shows promising ...

State Key Laboratory of Heavy Oil Processing, College of Chemistry and Chemical Engineering, China University of Petroleum (East China), Qingdao 266580, China ...

These can include neuromuscular disorders such as myasthenia gravis and muscular dystrophy. Ambrose explains that right now, the diagnosis can only be confirmed with molecular genetic testing ...